Antibodies as snakebite antivenoms

dc.contributor.authorSILVA, WILMAR D. dapt_BR
dc.contributor.authorANDRADE, SONIA A. dept_BR
dc.contributor.authorMEGALE, ANGELA A.A.pt_BR
dc.contributor.authorSOUZA, DANIEL A. dept_BR
dc.contributor.authorSANTANNA, OSVALDO A.pt_BR
dc.contributor.authorMAGNOLI, FABIO C.pt_BR
dc.contributor.authorGUIDOLIN, FELIPE R.pt_BR
dc.contributor.authorGODOI, KEMILY S.pt_BR
dc.contributor.authorSALADINI, LUCAS Y.pt_BR
dc.contributor.authorSPENCER, PATRICK J.pt_BR
dc.contributor.authorPORTARO, FERNANDA C.V.pt_BR
dc.coverageInternacionalpt_BR
dc.date.accessioned2022-12-19T15:20:52Z
dc.date.available2022-12-19T15:20:52Z
dc.date.issued2022pt_BR
dc.description.abstractSnakebite envenomation is considered a neglected tropical disease, affecting tens of thousands of people each year. The recommended treatment is the use of antivenom, which is composed of immunoglobulins or immunoglobulin fragments obtained from the plasma of animals hyperimmunized with one (monospecific) or several (polyspecific) venoms. In this review, the efforts made in the improvement of the already available antivenoms and the development of new antivenoms, focusing on snakes of medical importance from sub-Saharan Africa and Latin America, are described. Some antivenoms currently used are composed of whole IgGs, whereas others use F(ab’)2 fragments. The classic methods of attaining snake antivenoms are presented, in addition to new strategies to improve their effectiveness. Punctual changes in immunization protocols, in addition to the use of cross-reactivity between venoms from different snakes for the manufacture of more potent and widely used antivenoms, are presented. It is known that venoms are a complex mixture of components; however, advances in the field of antivenoms have shown that there are key toxins that, if effectively blocked, are capable of reversing the condition of in vivo envenomation. These studies provide an opportunity for the use of monoclonal antibodies in the development of new-generation antivenoms. Thus, monoclonal antibodies and their fragments are described as a possible alternative for the production of antivenoms, regardless of the venom. This review also highlights the challenges associated with their development.pt_BR
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)pt_BR
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)pt_BR
dc.description.sponsorshipIDFAPESP: 13/07467-1; 19/20832-7pt_BR
dc.description.sponsorshipIDCNPq: 490048/2005-6pt_BR
dc.format.extent1-13pt_BR
dc.identifier.citationSILVA, WILMAR D. da; ANDRADE, SONIA A. de; MEGALE, ANGELA A.A.; SOUZA, DANIEL A. de; SANTANNA, OSVALDO A.; MAGNOLI, FABIO C.; GUIDOLIN, FELIPE R.; GODOI, KEMILY S.; SALADINI, LUCAS Y.; SPENCER, PATRICK J.; PORTARO, FERNANDA C.V. Antibodies as snakebite antivenoms: past and future. <b>Toxins</b>, v. 14, n. 9, p. 1-13, 2022. DOI: <a href="https://dx.doi.org/10.3390/toxins14090606">10.3390/toxins14090606</a>. Disponível em: http://repositorio.ipen.br/handle/123456789/33478.
dc.identifier.doi10.3390/toxins14090606pt_BR
dc.identifier.fasciculo9pt_BR
dc.identifier.issn2072-6651pt_BR
dc.identifier.orcid0000-0001-8949-7735pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0001-8949-7735
dc.identifier.percentilfi72.4pt_BR
dc.identifier.percentilfiCiteScore82pt_BR
dc.identifier.urihttp://repositorio.ipen.br/handle/123456789/33478
dc.identifier.vol14pt_BR
dc.relation.ispartofToxinspt_BR
dc.rightsopenAccesspt_BR
dc.subjectantibodies
dc.subjecttoxins
dc.subjectvenoms
dc.subjectsnakes
dc.subjectdiseases
dc.subjectimmunoglobulins
dc.titleAntibodies as snakebite antivenomspt_BR
dc.typeArtigo de periódicopt_BR
dspace.entity.typePublication
ipen.autorPATRICK JACK SPENCER
ipen.codigoautor910
ipen.contributor.ipenauthorPATRICK JACK SPENCER
ipen.date.recebimento22-12
ipen.identifier.fi4.2pt_BR
ipen.identifier.fiCiteScore7.5pt_BR
ipen.identifier.ipendoc29112pt_BR
ipen.identifier.iwosWoSpt_BR
ipen.identifier.ods3
ipen.range.fi3.000 - 4.499
ipen.range.percentilfi50.00 - 74.99
ipen.subtitulopast and futurept_BR
ipen.type.genreArtigo
relation.isAuthorOfPublication4eb7939e-aeea-4991-8525-b3d05ac27364
relation.isAuthorOfPublication.latestForDiscovery4eb7939e-aeea-4991-8525-b3d05ac27364
sigepi.autor.atividadeSPENCER, PATRICK J.:910:830:Npt_BR
Pacote Original
Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
29112.pdf
Tamanho:
856.03 KB
Formato:
Adobe Portable Document Format
Descrição:
Licença do Pacote
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Coleções